Catalent, Inc.(CTLT) Stock Research - Grey Stern Research
Loading...

Catalent, Inc. (CTLT) Stock Analysis

$61.85 (0.24%)

CTLT Financial Performance


Use the table below to view Catalent, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $61.70 -
52 Week Low $36.74 -
52 Week High $62.08 -
Market Cap $11.2 Billion 3/6
Gross Margin 30% 6/6
Profit Margin 2% 6/6
EBITDA margin 8% 6/6
Q3 - 2024 Revenue $1.3 Billion 2/6
Q3 - 2024 Earnings $23.0 Million 6/6
Q3 - 2024 Free Cash Flow $0 Million 6/6
Trailing 4 Quarters Revenue $4.4 Billion 3/6
Trailing 4 Quarters Earnings -$997.0 Million 5/6
Quarterly Earnings Growth 127% 2/6
Annual Earnings Growth -30% 4/6
Quarterly Revenue Growth 22% 1/6
Annual Revenue Growth 5% 2/6
Cash On Hand $289.0 Million 4/6
Short Term Debt $48.0 Million 3/6
Long Term Debt $4.9 Billion 2/6

Catalent, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Catalent, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/6
PS 2.55 3/6
PB 3.11 3/6
PC 38.75 3/6
Liabilities to Equity 1.71 2/6
ROA -0.10 5/6
ROE -0.28 5/6
Current Ratio 1.59 5/6
Quick Ratio 0.05 5/6
Long Term Debt to Equity 1.35 2/6
Debt to Equity 1.36 2/6
Burn Rate 1.58 3/6
Cash to Cap 0.03 3/6
CCR 6/6
EV to EBITDA 149.20 1/6
EV to Revenue 3.60 2/6

Company Details

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CEO: Mr. John Chiminski

Website: https://www.catalent.com

Address: 14 Schoolhouse Rd Somerset, NEW JERSEY

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—Specialty & Generic

Catalent, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Catalent, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Teleflex Incorporated TFX $8.7 Billion
West Pharmaceutical Services, Inc. WST $23.3 Billion
IQVIA Holdings Inc. IQV $36.4 Billion
Charles River Laboratories International, Inc. CRL $10.2 Billion
Bio-Rad Laboratories, Inc. BIO $9.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CTLT Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 1.3 Billion $23.0 Million
Q3 2024 $ 1.1 Billion -$101.0 Million
Q2 2024 $ 1.0 Billion -$204.0 Million
Q1 2024 $ 982.0 Million -$715.0 Million
Q4 2023 $ 1.1 Billion -$86.0 Million
Q3 2023 $ 1.0 Billion -$227.0 Million
Q2 2023 $ 1.1 Billion $81.0 Million
Q1 2023 $ 1.0 Billion $0

View All

CTLT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $289.0 Million $9.8 Billion $4.9 Billion $3.6 Billion
Q3 2024 $162.0 Million $9.9 Billion $5.0 Billion $3.6 Billion
Q2 2024 $229.0 Million $10.0 Billion $5.0 Billion $3.7 Billion
Q1 2024 $209.0 Million $10.0 Billion $4.9 Billion $3.9 Billion
Q4 2023 $280.0 Million $10.8 Billion $4.8 Billion $4.6 Billion
Q3 2023 $252.0 Million $10.8 Billion $4.8 Billion $4.7 Billion
Q2 2023 $442.0 Million $11.1 Billion $4.9 Billion $4.9 Billion
Q1 2023 $281.0 Million $10.2 Billion $4.2 Billion $4.7 Billion

View All

CTLT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$62.0 Million -$74.0 Million -$67.0 Million
Q2 2024 -$44.0 Million $0 -$44.0 Million
Q1 2024 -$70.0 Million $0 -$71.0 Million
Q4 2023 $75.0 Million -$128.0 Million $28.0 Million
Q3 2023 -$202.0 Million -$138.0 Million -$190.0 Million
Q2 2023 $46.0 Million -$168.0 Million $161.0 Million
Q1 2023 -$241.0 Million -$149.0 Million -$168.0 Million
Q4 2022 -$166.0 Million -$235.0 Million -$337.0 Million

View All